# An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

> **NCT01178411** · PHASE1,PHASE2 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 60 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Tivantinib
- **DRUG:** Anti-Cancer Combination Therapy

## Key facts

- **NCT ID:** NCT01178411
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-31
- **Primary completion:** 2019-01-14
- **Final completion:** 2019-01-14
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01178411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01178411, "An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01178411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*